Washington University School of Medicine (WUSM) in St. Louis now leads a Phase 3 clinical trial, funded by the National Institutes of Health (NIH), testing the potential of three inflammatory disease-drugs in a bid to address and treat the cytokine storm associated with the novel coronavirus as well as shorten hospital stays and reduce the need for dependence on ventilators to augment breathing.
SARS-CoV-2 has been associated with autoimmune disease-like conditions once a patient is done with the viral infection. For months after, an individual’s immune system can produce immune proteins at the already vanquished virus, writes Julia Evangelou Strait for the WUSM St. Louis News Hub. This reaction can lead to dangerous conditions such as the cytokine storm, which can add to acute respiratory distress syndrome (ADDS) and multiple organ failure, and ultimately death.
William G. Powderly, MD, protocol chair of the international trial and also the J. William Campbell Professor of Medicine and director of the Institute of Clinical and Translational Sciences, commented on this situation, noting, “In severe COVID-19 infection, we think the virus triggers an abnormal ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).